Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

semaglutide

A glucagon-like peptide-1 (GLP-1) receptor agonist that is 94% homologous to human GLP-1 (7-37), with antihyperglycemic and appetite regulating activities. Upon administration, semaglutide binds to and activates GLP-1 receptor. In pancreatic beta cells, this increases glucose-dependent insulin release. Semaglutide also reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas and slows gastric emptying. Altogether this lowers the postprandial glucose level. In the brain, the binding to and activation of GLP-1 receptor suppresses appetite, which decreases caloric intake and lowers body weight. GLP-1 is normally secreted by L cells of the gastrointestinal (GI) mucosa in response to a meal to normalize blood glucose levels. It also plays an important role in the regulation of appetite and caloric intake
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:Ozempic
Rybelsus
Wegovy
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search